ATR and non-small cell lung carcinoma: NSCLC circulating tumor cell-derived xenograft (CDX) models and cell lines with high SLFN11 protein expression were more sensitive to PARP inhibitors, and CDX models and cell lines with high SLFN11 protein expression exhibited stronger metastatic potential and potential SCLC histological transformation (53).NSCLC cell lines with low SLFN11 expression and high cMYC expression demonstrated higher sensitivity to combined AXL/ATR inhibition therapy (54).